The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Stepanov I.A.

Irkutsk State Medical University

beloborodov V.A.

Irkutsk State Medical University

Shameeva M.A.

Irkutsk State Medical University

Borisov E.B.

Buryat Republican Clinical Oncology Dispensary

Shagdurova I.A.

Buryat Republican Clinical Oncology Dispensary

Use of the measured diffusion coefficient for predicting overall and progression-free survival rates in patients with recurrent glioblastoma treated with bevacizumab

Authors:

Stepanov I.A., beloborodov V.A., Shameeva M.A., Borisov E.B., Shagdurova I.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2020;9(6): 51‑58

DOI: 10.17116/onkolog2020906151

Read: 957 times

Download PDF (RU)
Contact the author
Table of contents

USE OF THE MEASURED DIFFUSION COEFFICIENT FOR PREDICTING OVERALL AND PROGRESSION-FREE SURVIVAL RATES IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB
USE OF THE MEASURED DIFFUSION COEFFICIENT FOR PREDICTING OVERALL AND PROGRESSION-FREE SURVIVAL RATES IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB

To cite this article:

Stepanov IA, beloborodov VA, Shameeva MA, Borisov EB, Shagdurova IA. Use of the measured diffusion coefficient for predicting overall and progression-free survival rates in patients with recurrent glioblastoma treated with bevacizumab. P.A. Herzen Journal of Oncology. 2020;9(6):51‑58. (In Russ.)
https://doi.org/10.17116/onkolog2020906151

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Long-term clinical outcomes of patients with loca­lly adva­nced gastric adenocarcinoma after two indu­ction cycles of chemotherapy acco­rding to the FLOT regi­men followed by chemoradiotherapy and radi­cal surgery. P.A. Herzen Journal of Onco­logy. 2025;(2):5-12
Effi­cacy of chemoimmunotargeted therapy in patients with adva­nced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Onco­logy. 2025;(3):63-70
Multivisceral surgeries with pancreatoduodenectomy for gastric cancer: imme­diate and long-term resu­lts. Piro­gov Russian Journal of Surgery. 2025;(8):30-38
Abstract:

Counting the values of the measured diffusion coefficient (MDC) in patients with recurrent glioblastoma (GB) treated with bevacizumab plays a role as a predictor for overall and progression-free survival (OS, PFS) rates. The studies investigating this problem have a retrospective design, while the findings are ambiguous and largely contradictory.

OBJECTIVE

To investigate the use of MDC for predicting OS and PFS rates in patients with recurrent GB treated with bevacizumab.

MATERIAL AND METHODS

A multicenter prospective cohort nonrandomized study was performed, which enrolled patients whose diagnosis of recurrent GB was clinically, instrumentally, and pathomorphologically confirmed.

RESULTS

Based on the compliance criteria, the study enrolled 53 patients with recurrent GB. Univariate analysis clearly showed that the MDCmin acted as a statistically significant predictor for OS (p=0.04) and PFS (p=0.01). On the other hand, the determination of the MDCmean did not significantly affect OS (p=0.18) and PFS (p=0.23). The results of multivariate analysis using the Cox proportional hazards model demonstrated the significant effect of the MDCmin values on PFS rates (p=0.01) in patients with recurrent GB compared with OS ones (p=0.16). The MDCmean, age, Karnofsky index, the use of glucocorticosteroid hormones, the type of recurrent GB, and a bevacizumab therapy regimen did not have a statistically significant effect on OS.

CONCLUSION

Counting the MDCmin values significantly affects PFS rates in patients with recurrent GB treated with bevacizumab and does not significantly affect their OS. The MDCmin values of more than 1200 mm2/sec for recurrent GB are associated with significantly higher PFS rates.

Keywords:

recurrent glioblastoma
diffusion-weighted MRI
measured diffusion coefficient
bevacizumab
overall survival
progression-free survival

Authors:

Stepanov I.A.

Irkutsk State Medical University

beloborodov V.A.

Irkutsk State Medical University

Shameeva M.A.

Irkutsk State Medical University

Borisov E.B.

Buryat Republican Clinical Oncology Dispensary

Shagdurova I.A.

Buryat Republican Clinical Oncology Dispensary

Received:

09.03.2020

Accepted:

29.06.2020

Close metadata

References:

  1. Batash R, Asna N, Schaffer P, Francis N, Schaffer M. Glioblastoma multiforme, diagnosis and treatment. Recent literature review. Curr Med Chem. 2017;24(27):3002-3009. https://doi.org/10.2174/0929867324666170516123206
  2. Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med. 2014;6(11):1359-1370. https://doi.org/10.15252/emmm.201302627
  3. Witthayanuwat S, Pesee M, Supaadirek C, Supakalin N, Thamronganantasakul K, Krusun S. Survival analysis of glioblastoma multiforme. Asian Pac J Cancer Prev. 2018;19(9):2613-2617. https://doi.org/10.22034/APJCP.2018.19.9.2613
  4. Keller S, Schmidt MHH. EGFR and EGFRvIII promote angiogenesis and cell invasion in glioblastoma: combination therapies for an effective treatment. Int J Mol Sci. 2017;18(6):1295. https://doi.org/10.3390/ijms18061295
  5. Mikkelsen VE, Stensjøen AL, Granli US, Berntsen EM, Salvesen Ø, Solheim O, Torp Sh. Affiliations expand angiogenesis and radiological tumor growth in patients with glioblastoma. BMC Cancer. 2018;18(1):862.  https://doi.org/10.1186/s12885-018-4768-9
  6. Byvaltsev VA, Stepanov IA, Belykh EG, Yarullina AI. Molecular aspects of angiogenesis in brain glioblastomas. Problems in Oncology. 2017;63(1):19-27. (In Russ.).
  7. Byvaltsev VA, Stepanov IA, Shameeva MA, Tetyushkin NA. Efectiveness of vascular endothelial growth factor inhibitors in the treatment of glioblastoma: a systematic review and meta-analysis. Problems in Oncology. 2019;65(4):546-555. (In Russ.).
  8. Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381-397.  https://doi.org/10.1016/B978-0-12-802997-8.00023-2
  9. Chinot OL, Wick W, Mason W, Henriksson R, Frank Saran, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.  https://doi.org/10.1056/NEJMoa1308345
  10. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MCJ, Buter J, Honkoop AH, Boerman D, de Vos FYF, Dinjens WNM, Enting RH, Taphoorn MJB, van den Berkmortel FWPJ, Jansen RLH, Brandsma D, Bromberg JEC, Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943-953.  https://doi.org/10.1016/S1470-2045(14)70314-6
  11. Xiao Q, Yang S, Ding G, Luo M. Anti-vascular endothelial growth factor in glioblastoma: a systematic review and meta-analysis. Neurol Sci. 2018;39(12):2021-2031. https://doi.org/10.1007/s10072-018-3568-y
  12. Lombardi G, Pambuku A, Bellu L, Farina M, Della Puppa A, Denaro L, Zagonel V. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2017;111:94-102.  https://doi.org/10.1016/j.critrevonc.2017.01.018
  13. Taourel P. Diffusion-weighted MRI for Breast Cancer: Why and with What Impact? Radiology. 2019;291(2):308-309.  https://doi.org/10.1148/radiol.2019190331
  14. Tamada T, Sone T, Jo Y, Yamamoto A, Ito K. Diffusion-weighted MRI and its role in prostate cancer. NMR Biomed. 2014;27(1):25-38.  https://doi.org/10.1002/nbm.2956
  15. Messiou C, Kaiser M. Whole body diffusion weighted MRI — a new view of myeloma. Br J Haematol. 2015;171(1):29-37.  https://doi.org/10.1111/bjh.13509
  16. Terada Y, Toda H, Okumura R, Ikeda N, Yuba Y, Katayama T, Iwasaki K. Reticular appearance on gadolinium-enhanced T1- and diffusion-weighted MRI, and low apparent diffusion coefficient values in microcystic meningioma cysts. Clin Neuroradiol. 2018;28(1):109-115.  https://doi.org/10.1007/s00062-016-0527-y
  17. Maximov II, Tonoyan AS, Pronin IN. Differentiation of glioma malignancy grade using diffusion MRI. Phys Med. 2017;40:24-32.  https://doi.org/10.1016/j.ejmp.2017.07.002
  18. Jain R, Scarpace LM, Ellika S, Torcuator R, Schultz LR, Hearshen D, Mikkelsen T. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol. 2010;96(3):423-431.  https://doi.org/10.1007/s11060-009-9981-6
  19. Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol. 2011;102(1):95-103.  https://doi.org/10.1007/s11060-010-0293-7
  20. Buemi F, Guzzardi G, Del Sette B, Sponghini AP, Matheoud R, Soligo E, Trisoglio A, Carriero A, Stecco A. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme. Neuroradiol J. 2019;32(4):241-249.  https://doi.org/10.1177/1971400919847184
  21. Galla N, Chiang G, Chakraborty S, Singh R, Tsiouris AJ, Boockvar J, Kovanlikaya I. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma. Neuroradiology. 2017;59(5):499-505.  https://doi.org/10.1007/s00234-017-1820-4
  22. Wang CW, Lai JC. Reporting functional status in UNOS: The weakness of the Karnofsky Performance Status Scale. Clin Transplant. 2017;31(7):10.1111/ctr.13004. https://doi.org/10.1111/ctr.13004
  23. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015;16(6):e270-e278. https://doi.org/10.1016/S1470-2045(15)70057-4
  24. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. https://doi.org/10.1001/jama.2013.281053
  25. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Phioanh N, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182-189.  https://doi.org/10.1148/radiol.2521081534
  26. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung W-KA, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Lada P, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012;108(3):491-498.  https://doi.org/10.1007/s11060-012-0847-y
  27. Paldino MJ, Desjardins A, Friedman HS, Vredenburgh JJ, Barboriak DP. A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. Br J Radiol. 2012;85(1012):382-389.  https://doi.org/10.1259/bjr/24774491
  28. O’Connor JP, Carano RA, Clamp AR, Ross J, Ho CCK, Jackson A, Parker GLM, Rose CJ, Peale FV, Friesenhahn M, Mitchell CL, Watson Y, Roberts C, Hope L, Cheung S, Reslan HB, Go MAT, Pacheco JG, Wu X, Cao TC, Sarajane R, Buonaccorsi GA, Davies K, Hasan J, Thornton P, del Puerto O, Ferrara N, van Bruggen N, Jayson GC. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res. 2009;15(21):6674-6682. https://doi.org/10.1158/1078-0432.CCR-09-0731
  29. Zhang M, Gulotta B, Thomas A, Kaley T, Karimi S, Gavrilovic I, Woo RM, Zhang Z, Arevalo-Perez J, Holodny AI, Rosenblum M, Young RJ. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. Neuro Oncol. 2016;18(5):735-743.  https://doi.org/10.1093/neuonc/nov268
  30. LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi JA, Malkin MG, Mueller WM, Schmainda KM. Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. Neuro Oncol. 2014;16(12):1599-1606. https://doi.org/10.1093/neuonc/nou142
  31. Pope WB, Lai A, Mehta R, Qiao J, Young JR, Xue X, Goldin J, Brown MS, Nghiemphu PL, Tran A, Cloughesy TF. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32(5):882-889.  https://doi.org/10.3174/ajnr.A2385
  32. Moon WJ, Choi JW, Roh HG, Lim SD, Koh YC. Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology. 2012;54(6):555-563.  https://doi.org/10.1007/s00234-011-0947-y
  33. Sunwoo L, Choi SH, Park CK, Kim JW, Yi KS, Lee WJ, Yoon TJ, Song SW, Kim JE, Kim JY, Kim TM, Lee S-H, Kim J-H, Sohn C-H, Park S-, Kim IH, Chang K-H. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme. J Magn Reson Imaging. 2013;37(2):351-358.  https://doi.org/10.1002/jmri.23838
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.